Creative Proteomics Leads the Way with Cutting-Edge RNA Pull Down Service

HERMES PHARMA announces €25 million investment to bolster capacity

HERMES PHARMA, the leading expert in user-friendly oral dosage forms, has announced it will invest €25 million to further bolster its manufacturing capabilities.

Announcing Kivo GO: An intuitive DMS to accelerate speed-to-market for life sciences

Kivo today introduced Kivo GO, a unified platform for emerging life sciences teams who need to work together efficiently across all functions while maintaining compliance and security.

Cytel continues expansion of market access and medical communication capabilities with the acquisition of co.faktor

Cytel Inc. has acquired the Berlin-based company co.faktor GmbH.

LIXTE Appoints Bas van der Baan as President and Chief Executive Officer

LIXTE Appoints Bas van der Baan as President and Chief Executive Officer

Discovery Park selects 13 start-ups to join Discovery Spark life science programme

Thirteen life science start-ups have been accepted onto Discovery Park’s new business support programme and competition, Discovery Spark. The eight-week Discovery Spark programme will equip the early-stage companies with the necessary skills to catalyse their business growth plans and gives them the chance to win a business support package worth over £100,000.

Sygnature Discovery successfully identifies potent SHP2 degrader compounds using its proprietary targeted protein degrader platform, CHARMED, in collaboration with Japanese specialty chemical company, UBE Corporation

Optibrium Releases Powerful Metabolism Prediction Capability in Next Generation StarDrop Software

Optibrium, a leading developer of software and AI solutions for drug discovery, today launched the latest version of its drug discovery platform, StarDrop 7.5, introducing a powerful module for drug metabolism prediction.

DRIVING PRECISION MEDICINE FORWARD: BIO-IT WORLD EUROPE CONVENES IN LONDON 29-30 NOVEMBER 2023

Bio-IT World Europe will convene in London 29-30 November 2023 to foster collaboration among the UK and Europe's biopharma and technology leaders who are forging new frontiers in precision medicine.

CD Genomics Unveils Cutting-Edge DNA 6mA Sequencing Service for Epigenomic Research

Creative Enzymes Unveils Custom Blends Product Line for Bioprocessing Solutions

CD Genomics Unveils Genotyping by Sequencing (GBS) -Revolutionizing Genomic Research

CD Genomics Redefines RNA Sequencing with Revolutionary Ultra Low RNA Sequencing Technology

Creative Enzymes Launches Diamine Oxidase (Food-Grade) for Enhanced Food Safety and Digestive Health

908 Devices Launches MAVERICK for Real-Time In-Line Monitoring of Multiple Bioprocess Parameters

MAVERICK is a Raman-based PAT solution that requires no complex modeling. It is an optical in-line analyzer that provides real-time monitoring and control of glucose, lactate, and total biomass in mammalian cell cultures, in addition to rich process fingerprint data to support large-scale efforts in predictive bioprocess modeling. MAVERICK is also the first turn-key device to utilize Raman spectroscopy for bioprocess control, with no modeling and development required. With its in-line optical sampling probe, biopharmaceutical scientists and engineers can quickly develop their cell culture media and design feeding and control strategies.

Health Plan of San Joaquin Selects ZeOmega to Elevate Complete Care Management

Health Plan of San Joaquin (HPSJ) just announced they selected ZeOmega’s care management solution to support the complex health needs of 450,000+ Medi-Cal members and promote equitable care statewide. HPSJ will use ZeOmega’s platform to consolidate and analyze members’ health data to produce insights informing care needs. The partnership will empower HPSJ to support members’ physical, mental, and behavioral health needs and align with CalAIM’s whole-person approach to healthcare.

Alfa Chemistry: Transforming Research Possibilities through Instrumental Analytical Reagents

NICE RECOMMENDS LILLY’S MIRIKIZUMAB (OMVOH ®▼) FOR THE TREATMENT OF ELIGIBLE ADULTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS

Mirikizumab is the first IL-23p19 targeted biologic recommended by NICE for use within NHS England and Wales for treating moderately to severely active ulcerative colitis in adults.1,2. In two randomised, double-blind, placebo-controlled phase 3 trials, LUCENT-1 and LUCENT-2, mirikizumab achieved primary and key secondary endpoints, including sustained clinical remission. Decreases in bowel urgency severity were observed as early as week 2 in patients treated with mirikizumab versus placebo in LUCENT-1.2 Mirikizumab has been recommended through the NICE cost-comparison process meaning NHS England and commissioning groups have agreed to provide funding to implement this guidance within 30 days from publication of the technology appraisal guidance (TAG) rather than the standard 90 days, providing faster access to a new treatment option for eligible adults living with moderately to severely active ulcerative colitis1

Expanding Research Frontiers: CD Formulation Enables In Vitro Cytotoxicity Testing for Microspheres and Microneedles

Bora merges with Sunway Biotech to launch global Nutraceuticals offering